REPROCELL files for manufacturing and market approval for Stemchymal® in Japan. This treatment targets spinocerebellar ataxia SCA3 and SCA6.

REPROCELL Inc. has submitted a manufacturing and marketing authorization request in Japan for Stemchymal®, aimed at treating spinocerebellar ataxia.

REPROCELL announces its application for approval to market its stem cell therapy, Stemchymal®, aimed at treating spinocerebellar ataxia in Japan, highlighting a significant advancement in therapeutic options.

REPROCELL has submitted a crucial application in Japan for its regenerative medicine product, Stemchymal®, aimed at treating SCA3 and SCA6, targeting significant medical needs.

Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...

Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...

YOKOHAMA, Japan, 24. Juni 2026 /PRNewswire/ -- REPROCELL Inc. gab heute bekannt, dass das Unternehmen einen Antrag auf Zulassung für die Herstellung und das Inverkehrbringen des regenerativen Medizinprodukts Stemchymal® in Japan gestellt hat, für das das Unternehmen die exklusiven...

BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ — REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready […]

REPROCELL (TYO: 4978) today announced that it has received a competitive Commercialization Award from the Maryland Stem Cell Research Fund (MSCRF).

REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA).

New offering combines iPSC technology and AI-driven editing design to support translational and clinical research.

The human iPSC control lines (1210B2 and RPC771 (ReproCELL)) and the genome-edited derivative of RPC771 (ΔEx15) were maintained as previously described50,65. The cells were cultured under feeder-free conditions in StemFit AK03N medium (Ajinomoto) on culture surfaces coated with 0.25 μg/cm2...

REPROCELL has initiated the production of a GMP-compliant Master Cell Bank, enhancing their clinical iPSC services to streamline therapy development.

REPROCELL has introduced GMP-compliant Master Cell Banks for clinical induced pluripotent stem cells (iPSCs), streamlining the process for cell therapy development.

REPROCELL has launched a GMP Master Cell Bank for iPSCs, streamlining the cell therapy development process with FDA compliance and integrated services.

REPROCELL has launched a new service for the production of induced pluripotent stem cells, ensuring compliance with FDA Good Manufacturing Practices. This service enhances efficiency for cellular therapy developers.

REPROCELL's introduction of StemEdit marks a significant advancement in clinical gene editing, facilitating safer, scalable solutions for cell therapy developers.

REPROCELL USA has secured a significant grant from the Maryland Stem Cell Research Fund to establish a GMP manufacturing organization, advancing regenerative medicine.